Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________________________ Form 10-K ________________________________________________________________________________________________________ For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-365 ...

For the quarter ended December 2025, CareDx (CDNA) reported revenue of $108.39 million, up 25.2% over the same period last year. EPS came in at $0.12, compared to $0.18 in the year-ago quarter.The reported revenue represents a surprise of +5.66% over the Zacks Consensus Estimate of $102.58 million. With the consensus EPS estimate being $0.24, the EPS surprise was -48.94%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ex ...

CareDx (CDNA) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -48.94%. A quarter ago, it was expected that this molecular diagnostics company would post earnings of $0.13 per share when it actually produced earnings of $0.28, delivering a surprise of +115.38%.Over the last four quarte ...

CareDx (NasdaqGM:CDNA) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAndrew Cooper - VP of Equity ResearchBrandon Couillard - Managing DirectorCaroline Corner - Director of Investor RelationsJohn Hanna - President and CEOKeith Kennedy - COONathan Smith - CFOTycho Peterson - Managing DirectorConference Call ParticipantsAndrew Brackmann - Equity Research AnalystBill Bonello - Senior Research AnalystEduardo Martinez - Equity Research AnalystMason Carrico - Research AnalystVivian Cerva ...

CareDx (NasdaqGM:CDNA) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAndrew Cooper - VP of Equity ResearchBrandon Couillard - Managing DirectorCaroline Corner - Director of Investor RelationsJohn Hanna - President and CEOKeith Kennedy - COONathan Smith - CFOTycho Peterson - Managing DirectorConference Call ParticipantsAndrew Brackmann - Equity Research AnalystBill Bonello - Senior Research AnalystEduardo Martinez - Equity Research AnalystMason Carrico - Research AnalystVivian Cerva ...

CareDx (NasdaqGM:CDNA) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker9Hello, everyone. Thank you for joining us, welcome to the CareDx Q4 2025 financial results earnings call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. To withdraw your question, press star one again. I will now hand the call over to Caroline Corner, Investor Relations. Please go ahead.Speaker4Thank you, operator ...

Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this presentation, including statements regarding the future financial position of CareDx®, Inc. (together with its subsidiaries, "CareDx" or the "Company"), including financial targets and ...

Financial Results - CareDx, Inc. announced preliminary unaudited financial results for the quarter and year ended December 31, 2025[4] - The financial results will be further detailed in the attached press release, which is incorporated by reference[5] Press Release - The press release detailing these results was issued on January 12, 2026[4] Company Information - The company is listed on The Nasdaq Stock Market under the trading symbol CDNA[2] - CareDx, Inc. is not classified as an emerging growth company[3]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - CareDx (CDNA) announced clinical validation data for AlloHeme, a blood-based monitoring test aimed at predicting relapses in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) post-allogeneic hematopoietic cell transplant (HCT) [1][4] Group 1: AlloHeme Test Details - AlloHeme utilizes next-generation sequencing and artificial intelligence to enhance sensitivity in detecting early relapse signals compared to traditional methods [2][4] - The ACROBAT clinical study demonstrated that AlloHeme achieved 85% sensitivity and 92% specificity, detecting relapses a median of 41 days earlier than standard clinical diagnosis [9][12] - The assay's performance metrics indicate a 95% negative predictive value and a 79% positive predictive value, with an area under the curve of 0.89 [11] Group 2: Commercialization and Market Strategy - CareDx plans to roll out AlloHeme in the U.S. starting with CLIA readiness in 2026, followed by commercialization in 2027 and expected payer coverage by 2028 [3][9] - The company aims to expand its Transplant+ strategy into cell therapy and hematologic oncology, addressing unmet needs in AML and MDS monitoring [3][6] - The integrated offering will combine diagnostics, digital tools, and patient support solutions tailored for the cell therapy ecosystem [4][7] Group 3: Market Performance and Growth Potential - Following the announcement, CDNA shares increased by 2.8%, with a 65.6% rise over the past six months, significantly outperforming the industry and S&P 500 [5] - The clinical validation of AlloHeme is seen as a significant growth catalyst, enhancing CareDx's position in the cell therapy and hematologic oncology markets [6][7] - The cell therapy market is projected to reach $9.13 billion by 2026, with a compound annual growth rate (CAGR) of 22.9% through 2034, driven by advancements in technology and increasing disease prevalence [14][15]